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ABSTRACT
Introduction Limited data exist on the epidemiology of acute 
hypoxaemic respiratory failure (AHRF) in low- income countries 
(LICs). We sought to determine the prevalence of AHRF in 
critically ill adult patients admitted to a Ugandan tertiary referral 
hospital; determine clinical and treatment characteristics as 
well as assess factors associated with mortality.
Materials and methods We conducted a prospective 
observational study at the Mulago National Referral and 
Teaching Hospital in Uganda. Critically ill adults who were 
hospitalised at the emergency department and met the criteria 
for AHRF (acute shortness of breath for less than a week) were 
enrolled and followed up for 90 days. Multivariable analyses 
were conducted to determine the risk factors for death.
Results A total of 7300 patients was screened. Of these, 
327 (4.5%) presented with AHRF. The majority (60 %) 
was male and the median age was 38 years (IQR 27–52). 
The mean plethysmographic oxygen saturation (SpO2) 
was 77.6% (SD 12.7); mean SpO2/FiO2 ratio 194 (SD 32) 
and the mean Lung Injury Prediction Score (LIPS) 6.7 (SD 
0.8). Pneumonia (80%) was the most common diagnosis. 
Only 6% of the patients received mechanical ventilatory 
support. In- hospital mortality was 77% with an average 
length of hospital stay of 9.2 days (SD 7). At 90 days 
after enrolment, the mortality increased to 85%. Factors 
associated with mortality were severity of hypoxaemia 
(risk ratio (RR) 1.29 (95% CI 1.15 to 1.54), p=0.01); a 
high LIPS (RR 1.79 (95% CI 1.79 1.14 to 2.83), p=0.01); 
thrombocytopenia (RR 1.23 (95% CI 1.11 to 1.38), p=0.01); 
anaemia (RR 1.15 (95% CI 1.01 to 1.31), p=0.03) ; HIV 
co- infection (RR 0.84 (95% CI 0.72 to 0.97), p=0.019) and 
male gender (RR 1.15 (95% CI 1.01 to 1.31) p=0.04).
Conclusions The prevalence of AHRF among emergency 
department patients in a tertiary hospital in an LIC was low 
but was associated with very high mortality. Pneumonia 
was the most common cause of AHRF. Mortality was 
associated with higher severity of hypoxaemia, high LIPS, 
anaemia, HIV co- infection, thrombocytopenia and being 
male.
INTRODUCTION
Acute hypoxaemic respiratory failure (AHRF) 
is a common cause of hospital admission 
and organ failure around the world.1 2 The 
severest form of AHRF is referred to as the 
acute respiratory distress syndrome (ARDS) 
and defined by the Berlin consensus (acute 
onset of hypoxaemia with PaO2/FiO2 ratio 
≤300 mm Hg at a PEEP of 5 cm H2O, bilat-
eral infiltrates on chest X- ray, with no need 
to exclude cardiac disease). Despite techno-
logical advances in mechanical respiratory 
support, the mortality of AHRF and ARDS 
remain high.2 3 Most of the published litera-
ture has focused on ARDS in the developed 
world.4 In a large Scandinavian study, the 
90- day mortality rate in patients with AHRF 
was similar to that in ALI/ARDS, namely, 41% 
and 42%, respectively.4 In low- income coun-
tries (LICs) and especially Africa, where ICU 
capacities and resources are highly limited,5 
there is paucity of data to describe the burden 
and epidemiology of AHRF or ARDS. Further-
more, the epidemiology of ARHF in LICs is 
poorly understood. One study conducted in 
Rwanda used a modification of the Berlin 
definition to determine the incidence of 
ARDS.6
Key messages
 ► What is the prevalence of adult acute hypoxaemic 
respiratory failure in an acute care clinical setting 
in an African country and what are the survival out-
comes of these patients?
 ► The mortality among adult patients presenting with 
AHRF in our study population was very high.
 ► This study provides the first direct evidence of the 
burden of AHRF in an African adult population pre-
senting to a hospital emergency department and 
suggests that the high mortality may be associated 
with lack of access to advanced oxygen therapy as 
well as lack of access to ICU admission.
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We undertook this prospective study among medically 
ill adult patients presenting to the emergency depart-
ment in a tertiary hospital in Kampala, Uganda, to deter-
mine the prevalence of and 90- day mortality from AHRF. 
Furthermore, we sought to determine risk factors associ-
ated with death in these patients.
METHODS
Study design
This study was designed as a prospective, observational, 
period prevalence study and was conducted in the emer-
gency department of the Mulago National Referral 
and Teaching Hospital in Kampala, Uganda, between 
1 November 2015 and 31 July 2017. Written informed 
consent was obtained from all study patients or their next 
of kin.
Patient and public involvement in the study
Patients and the public were not involved in the design, 
conduct, reporting or dissemination plans for this study.
Study setting
Mulago National Referral and Teaching Hospital is a 
1500- bed hospital located in Kampala, the capital city of 
Uganda. This hospital serves the population of Kampala, 
the capital city of Uganda, with 1.5 million inhabitants as 
well as the surrounding districts of Mukono and Wakiso 
with a total catchment population of 4 million people. 
The emergency department receives between 60 000 to 
72 000 patients per year and is divided into three major 
areas namely a surgical side handling surgical emer-
gency, a trauma resuscitation area and a medical side 
for medical emergencies. For purposes of our study we 
restricted ourselves to the medical side of the emergency 
department and focused on more severely ill patients 
with a Modified Early Warning Score >4.
A total of 13 nurses, 6 medical officers, 4 intern doctors 
and 1 full- time attending physician staffed the medical 
side of the emergency department. In addition, two senior 
house officers (internal medicine specialty trainees) and 
an on- call physician provide coverage on a rotational 
basis. The medical emergency ward was able to provide 
intermittent vitals monitoring as well as oxygen therapy. 
The emergency department did not provide non- invasive 
ventilation. In the emergency ward, patients spend 
24 hours, during which a provisional/working diagnosis 
is initially made, and then after a diagnostic workup and 
emergency management, it may be amended at 24- hour 
review when a disposition plan is being made. Patients 
are then transferred to specialist units to receive further 
in- hospital care.
The hospital runs one of the two public ICUs in the 
country. During the study period, the ICU had 12 
beds with the ability to ventilate six patients at any one 
time. It provides ICU services to all kinds of critically ill 
patients. The ICU can provide mechanical ventilation, 
postoperative care, intermittent haemodialysis, perito-
neal dialysis and basic neurocritical care. Patients in the 
emergency and intensive care units can get full blood 
count and blood group tests done free of charge and 
chemistry panels at a cost.
Study patients
All patients admitted to the ED with AHRF. AHRF was 
defined as acute shortness of breath of less than a week, 
with or without a history of cough, and a pulse oximetry 
reading of <91% on room air. We excluded patients who 
were younger than 18 years, patients with a poor prog-
nosis, or patients who were unconscious and without a 
proxy to provide written informed or deferred consent.
Informed consent
As far as possible, consent was obtained from patients. We 
obtained consent from the patients’ next of kin where 
the patient was too ill to give consent. In other cases, we 
obtained deferred consent, for patients who recovered 
within the study period. Additionally, due to the limited 
human resource in our setting, family members are often 
involved in in- hospital patient care and are therefore 
frequently available within hospital premises and are able 
to consent. Consent forms were translated into the local 
vernacular to aid communication.
Medical management of study patients
On recruitment, all patients received continuous oxygen 
therapy by nasal prongs (6 L/min) or venturi masks 
(10 L/min) to provide at least FiO2 of 0.4 to maintain 
SpO2 levels above 91% or as best as possible. This popu-
lation received treatment with conventional oxygen 
therapy (patients got oxygen therapy by face mask or 
nasal prongs with flow rates titrated against SPO2 >91% or 
as best as possible) and pneumonia management was in 
accordance with Ugandan national treatment guidelines 
(https://www. health. go. ug/ sites/ default/ files/ Uganda_ 
Clinical_ Guidelines_ 2016_ FINAL. pdf). We referred 
patients who deteriorated further to the ICU as and when 
resources and bed capacity permitted.
Our study defined anaemia as haemoglobin <8 g/dL, 
thrombocytopenia as platelets <100×109/L, leucocytosis 
as white cell count >12×109/L and leucopenia as white 
cell count <4×109/L. SPO2 <85% and mean arterial pres-
sure <65 mm Hg were considered low.
Data collection and processing
Using a standardised questionnaire, the study team 
obtained information on selected sociodemographic 
characteristics including age, gender, smoking status and 
firewood exposure. Additionally, clinical information 
such as previous health status and admission diagnosis 
as well as clinical and laboratory parameters (including 
predisposing conditions such as shock, sepsis, HIV status, 
pneumonia and risk modifiers such as need for higher 
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FiO2, hypoxaemia) were obtained to compute the Lung 
Injury Prediction Score (LIPS). LIPS is a validated score 
in which one can incorporate a series of routinely avail-
able risk factors and modifiers to predict which patients 
will develop ARDS.7 In this model a LIPS of 4 predicts 
development of ARDS. Clinical notes were reviewed 
24 hours after admission for change of or additional diag-
noses.
In the absence of arterial blood gas results, we used the 
widely accepted and validated SpO2/FiO2 ratio to repre-
sent severity of hypoxaemia at admission. We used the 
SpO2/FiO2 ratio <315 as our threshold ratio for ARDS.
8 
In all patients, pulse oximetry was measured by conven-
tional two- wavelength finger pulse oximeters. We consid-
ered the worst readable value of SpO2 at admission for 
our data.
At the end of each participant- researcher contact, case 
report forms were checked for completeness. We double 
entered the data into a computerised database (EpiData 
V.3.1)
Study end points
The primary outcome was the prevalence of AHRF 
among study patients. The secondary outcome was 90- day 
mortality and factors associated with mortality.
Statistical analysis
We conducted an 18- month period prevalence study. 
Prevalence of AHRF was computed using the total 
number of patients included as the denominator, and 
patients with AHRF as the numerator. Quantitative varia-
bles were described as mean (SD) or median (25th–75th 
centiles), as appropriate, and compared using Student’s 
t test or the Wilcoxon- Mann- Whitney test. Qualitative 
variables were described as counts (%) and compared 
using the χ2 or the Fisher’s exact test, as appropriate. The 
modified Poisson regression was used to determine the 
factors associated with mortality and this is expressed as 
risk ratios (RRs) with a two- sided p value level of signifi-
cance set at 0.05. We included variables found to be asso-
ciated with mortality in other acute care AHRF- related 
studies in our multivariate model, although they may not 
have been statistically significant at bivariate analysis.
RESULTS
We screened a total of 7300 acutely ill patients during the 
18- month study period from 1 November 2015 to 31 July 
2017. Of these, 327 patients met the eligibility criteria for 
AHRF. We excluded 6972 patients (figure 1). This repre-
sented a prevalence of acute respiratory failure of 4.5%. 
There was no difference between age and sex distribu-
tion at the screening and enrolment stages. The median 
age was 38 years (IQR 27–52) and the majority of the 
study patients (60%) was male (table 1). Of the 327 who 
presented with acute respiratory failure, 310 (94.5%) 
reported no previous history of acute respiratory failure. 
Cardiac disease was present in 28 (8.5%) and asthma in 
6 (1.8%) study participants. The most common cause of 
AHRF was pneumonia among 271 (82.6%). Co- infection 
with HIV was present in 101 (30%) of the participants. 
The mean plethysmographic oxygen saturation by pulse 
oximetry (on room air) was 77.6% (SD 12.7); mean 
SpO2/FiO2 ratio 193.9 (SD 31.8); mean LIPS 6.7 (SD 
0.8). Only 6% of the participants were admitted to the 
ICU where they received invasive mechanical ventilation.
Regarding mortality (table 2), 253 (77%) of the study 
participants died in hospital while cumulative mortality 
at 90- day follow- up was 85%. Using modified Poisson 
regression analysis, severity of hypoxaemia (RR 1.29 (95% 
CI 1.15 to 1.54), p=0.01); a high LIPS (RR 1.79 (95% CI 
1.14 to 2.83), p=0.01); thrombocytopenia (defined as 
<100) (RR 1.23 (95% CI 1.11 to 1.38), p=0.01); anaemia 
(RR 1.15 (95% CI 1.01 to 1.31), p=0.03); HIV- positive 
status (RR 0.84 (95% CI 0.72 to 0.97), p=0.019) and 
being male (RR 1.15 (95% CI 1.01 to 1.31), p=0.04) were 
independently associated with 90- day mortality (table 3). 
We found no statistically significant difference between 
mortality among those who received ICU care and those 
who did not. Unlike other studies, we did not find an 
association between older age and mortality.
DISCUSSION
Our study showed that AHRF was prevalent and associated 
with a high mortality in our population. The risk factors 
for death were pneumonia, severity of hypoxaemia, high 
Figure 1 Flow chart of study participants. EM, Emergency 
Medicine; MEWS, Modified Early Warning Score.
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LIPS, HIV co- infection, anaemia, thrombocytopenia and 
being male.
We conducted a period prevalence study because 
considering the resource limitations it was operationally 
less complex as compared with the cohort or case- control 
study.
Our patients were predominantly male, of a similar age 
range as African studies, but much younger than patients 
in high- income countries (HICs).9 10
The prevalence of AHRF in our study population was 
low. This is slightly similar to a study done in Rwanda in 
which hypoxia was found in 8% of hospitalised patients. 
The Kigali Study screened 1046 hospitalised patients over 
a 6- week period. This was lower than that reported in the 
Scandinavian and LUNGSAFE studies which reported 
incidences of AHRF of 23% and 34%, respectively. 
However, the LUNGSAFE Study did have some middle- 
income country data.
The main cause of AHRF in our study population was 
lower respiratory tract infection (LRTI). The majority 
of our study participants had pneumonia as a diagnosis. 
Community- acquired bacterial pneumonia was the most 
common cause of ARDS in data from other studies in the 
African setting.11
These findings concur with data suggesting that a 
young adult with LRTI in an LIC has a much higher odds 
of dying compared with one with LRTI in a high- income 
country.2 Similar findings were reported in the Rwanda 
Study where the most common underlying cause of respi-
ratory failure was infection. Our study however, found 
that none of the participants was assessed for microbio-
logical aetiology.
Our study found mortality to be very high among 
patients with AHRF. This was higher than that reported 
in the Kigali Study. This was even much higher than that 
reported in both the Scandinavian and the LUNGSAFE 
(Large observational study to Understand the Global 
Impact of Severe Acute Respiratory failure) studies, 
even though in these studies, mortality was almost 
identical between the patients with non- ARDS acute 
respiratory failure and patients with mild or moderate 
ARDS.2 4Mortality among our patients was higher than 
the overall mortality among adult patients admitted to 
the Mulago National Referral and Teaching Hospital with 
non- respiratory acute illness (from an audit conducted at 
the same time, the mortality rate for non- AHRF acutely 
ill patients was 48%).
The high mortality in our study may be explained by 
the fact that our patients were very sick. This may be 
evidenced by the fact that LIPS was very high; that patients 
were severely hypoxaemic at presentation; and that due 
to resource constraints (such as lack of ICU beds, fluid 
monitoring, etc) most of our patients who would have 
benefited from intensive care, were not able to access it.
LIPS has been used to identify patients at risk of devel-
oping ARDS. In that study, a cut- off of ≥4 predicted having 
ARDS or death.7 In our study, the average LIPS was more 
than 2 points above that cut- off. LIPS maybe useful in 
helping identify those high- risk patients in whom low cost 
interventions would possibly save, given the limited and 
often expensive treatment options available once ARDS 
has developed.
Severity of hypoxaemia is a predictor of mortality 
among patients with ARDS.12 Severe hypoxaemia (PaO2/
FiO2 < 100 mm Hg, at a PEEP (Positive End Expiratory 
Pressure) of 5 cm H2O), has been found in 20%–30% 
of patients with ARDS and is associated with the highest 
mortality rate.1 13 The mean non- invasive SpO2 in our 
study was 77%. Additionally, we also used the SpO2/
FiO2 ratio to determine the severity of hypoxaemia. 
This is now a widely accepted non- invasive method to 
determine severity of hypoxaemia in hypoxic acute lung 
disease.8 14 15 The mean SpO2/FiO2 ratio (193.9) in our 
study suggests that the majority of our study patients, and 
Table 1 Baseline characteristics at admission
Characteristic N (%)/327 (100)
Demographics
Age in years: median (IQR) 38 (27,52)
Male 197 (60.1)
Use firewood 121 (36.8)
Smoking history 50 (15)
Smoking pack years* 0.95 (0.63)
History of asthma 6 (1.8)
Previous history of acute lung injury 
admission
18 (5.5)
Diagnosis at 
admission
Pneumonia 271 (82.6)
Cardiac disease 28 (8.5)
Neurological disease 85 (25.9)
HIV- positive 101 (30.8)
Sepsis 100 (30.4)
Clinical 
characteristics†
Mean (SD)
Lung Injury Prediction Score 6.7 (0.8)
Heart rate 117.8 (22.8)
Respiratory rate 33.9 (8.9)
Mean arterial pressure (mm Hg) 78.6 (23.3)
Temperature (oC) 37.2 (1.1)
Pulse oximetry (SpO2) 77.6 (12.7)
SpO2/F ratio 193.9 (31.8)
White cell count (109/L)‡ 11.9 (8.3)
Haemoglobin status g/dL‡ 11.1 (3.9)
Platelet count (109/L)‡ 243.2 (139.1)
*Pack years (SD).
†Worst values were recorded in the 24 hours.
‡While patients got a full blood count done free of charge, only 
313/327 had Full Blood Count results available.
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Table 2 Bivariate analysis of factors associated with mortality
Characteristic
Outcome
n (% row)
Crude risk ratio
(95% CI) P value
Dead Alive
254 (77.7) 73 (22.3)
Sex
  Female 97 (74.6) 33 (25.4) 1
  Male 157 (79.7) 40 (20.3) 1.07 (0.94 to 1.21) 0.293
Previous history of acute lung injury 
admission
  No 240 (77.7) 69 (22.3) 1
  Yes 14 (77.8) 4 (22.2) 1.00 (0.78 to 1.29) 0.991
Smoked
  No 215 (77.6) 62 (22.4) 1
  Yes 39 (78.0) 11 (22.0) 1.00 (0.86 to 1.18) 0.952
Had asthma
  No 250 (77.9) 71 (22.1) 1
  Yes 4 (66.7) 2 (33.3) 0.86 (0.48 to 1.51) 0.593
Had pneumonia
  No 44 (77.2) 13 (22.8) 1
  Yes 210 (77.8) 60 (22.2) 1.01 (0.86 to 1.18) 0.924
Had a cardiac disease
  No 234 (78.3) 65 (21.7) 1
  Yes 20 (71.4) 8 (28.6) 0.91 (0.72 to 1.16) 0.459
Neuro
  Yes 186 (76.9) 56 (23.1) 1
  No 68 (80.0) 17 (20.0) 1.04 (0.92 to 1.18) 0.536
Liver
  No 245 (77.8) 70 (22.2) 1
  Yes 9 (75.0) 3 (25) 0.96 (0.69 to 1.34) 0.830
HIV status
  No 179 (79.2) 47 (20.8) 1
  Yes 75 (74.3) 26 (25.7) 0.94 (0.82 to 1.0.7) 0.341
Dead Discharged
SPO2 /FiO2
  <200 139 (88.0) 19 (12.0) 1
  201 or more 115 (68.1) 54 (31.9) 0.77 (0.69 to 0.87) <0.001
LIPS
  Low 14 (48.3) 15 (51.7) 1
  High (six or more) 240 (80.5) 58 (19.5) 1.67 (1.14 to 2.44) 0.009
Heart rate
  Normal 41 (74.6) 41 (25.4) 1
  Abnormal (>100) 205 (77.9) 58 (22.1) 1.05 (0.88 to 1.24) 0.602
Respiratory rate
26 (81.3) 6 (18.7) 1
74 (76.3) 23 (23.7) 0.94 (0.77 to 1.15) 0.538
154 (77.8) 44 (22.2) 0.96 (0.80 to 1.15) 0.639
MAP
  Normal 168 (72.4) 64 (27.6) 1
  Abnormal (<65) 86 (90.5) 9 (9.5) 1.25 (1.13 to 1.39) <0.001
Continued
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Characteristic
Outcome
n (% row)
Crude risk ratio
(95% CI) P value
SPO2%
  Normal (85+) 77 (64.2) 43 (35.8) 1
  Abnormal 177 (85.5) 30 (14.5) 1.33 (1.15 to1.54) <0.001
WBC×10 ul
  Normal 108 (68.3) 50 (31.7) 0.36 (0.13 to 0.98) 0.046
  Abnormal (>12 000 or <4000) 126 (84.6) 23 (15.4) 0.89 (0.30 to 2.60) 0.830
Haemoglobin (/dl)
  Normal 176 (75.2) 58 (24.8) 1
  Abnormal (<8) 55 (83.3) 11 (16.7) 1.11 (0.97 to 1.26) 0.124
Platelet count (×109/ul)
  Normal 166 (74.4) 57 (25.6) 1
  Abnormal (<100) 29 (96.7) 1 (3.3) 1.30 (1.17 to 1.44) <0.001
MAP, mean arterial pressure.
Table 2 Continued
Table 3 Multivariate analysis
Characteristic
Crude risk ratio
(95% CI) P value
Adjusted risk ratio
(95% CI) P value
Sex
  Female 1 1
  Male 1.07 (0.94 to 1.21) 0.293 1.15 (1.01 to 1.31) 0.044
HIV status
  No 1 1
  Yes 0.94 (0.82 to 1.0.7) 0.341 0.84 (0.72 to 0.97) 0.019
LIPS
  Low 1 1
  High (6 or more) 1.67 (1.14 to 2.44) 0.009 1.79 (1.14 to 2.83) 0.012
Heart rate
  Normal 1 1
  Abnormal (>100) 1.05 (0.88 to 1.24) 0.602 1.07 (0.89 to 1.29) 0.448
MAP
  Normal 1 1
  Abnormal (<65) 1.25 (1.13 to 1.39) <0.001 1.09 (0.98 to 1.22) 0.125
SpO2%
  Normal (85+) 1 1
  Abnormal (<85) 1.33 (1.15 to 1.54) <0.001 1.29 (1.10 to 1.51) 0.001
HBG/dl
  Normal 1 1
  Abnormal (<8) 1.11 (0.97 to 1.26) 0.124 1.15 (1.01 to 1.31) 0.028
Platelet count (×109/ul)
  Normal 1 1
  Abnormal (<100) 1.30 (1.17 to 1.44) <0.001 1.23 (1.11 to 1.38) <0.001
LIPS, Lung Injury Prediction Score; MAP, mean arterial pressure.
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using the AECC (American European Consensus Confer-
ence) definitions,16 had acute lung injury (ALI).
HIV co- infection was associated with higher mortality 
from respiratory failure, as seen in previous studies in 
Uganda.17 18 The immunosuppressive state is known 
to predispose to aggressive opportunistic infections 
that cause respiratory and other organ failures. The 
significance of the association between anaemia and 
thrombocytopenia with mortality in our study explains 
the high rate of infection and possible pulmonary 
sepsis. In sepsis, a low platelet count is a well- known 
biomarker for disease severity.19 This (in addition to 
hypotension) highlights the high incidence of sepsis in 
this study population. Hypotension was also a predictor 
of mortality among patients with pneumonia in a study 
conducted in Malawi.20 We did not employ sepsis iden-
tification strategies at the time of the study. The focus 
was on treatment of infection and not necessarily sepsis 
as a syndrome. A limitation in our study was we did not 
document how much fluid was administered to patients. 
A randomised fluid trial in Zambia was stopped early for 
possible harm in the subgroup of patients with hypox-
aemia and tachypnoea (who were receiving fluids).21 It 
is possible that in our study population, fluids given to 
treat hypotension caused more harm. However, hypo-
tension was not significantly associated with mortality 
at multivariate analysis.
Another possible explanation for the high mortality 
in our study was the lack of adequate resources to 
provide positive pressure ventilation to all patients 
that would benefit from it. Only 6% of the study partic-
ipants received mechanical ventilation. Even then, 
mortality among them was still high. Some data suggest 
that mechanically ventilated patients in LICs have a 
higher mortality than those in HICs.22 Other resource 
constraints such as staffing, skills and delays in accessing 
care may explain this.
The Rwanda Study used a modification of the Berlin 
definition to achieve their primary objective.6 They 
found that about 50% of all patients with an SpO2/FiO2 
ratio ≤315 (where their estimate of PaO2/FiO2 ≤300) 
met their criteria for ARDS. Both the LUNGSAFE Study 
and a study looking at the impact of high- flow oxygen 
in severe respiratory failure found that the majority of 
hypoxic patients met the criteria for ARDS.2 23 There-
fore, while our study was not able to apply the Berlin 
definition, it may seem logical that a large percentage 
of our hypoxic patients would have met clinical criteria 
for ARDS.
Our study had some limitations. Due to resource 
constraints, as previously documented, we were unable 
to perform arterial blood gas measurements in the study 
population. However, as documented earlier, we used a 
validated method to detect severity of hypoxaemia. We 
were unable to perform microbiological diagnoses such 
as blood cultures or sputum analyses. Other investiga-
tions were sporadic and inconsistent. We relied on clini-
cians’ judgement for diagnosis data, but the ward system 
ensured that an internal medicine specialist had reviewed 
the working diagnosis. Another likely limitation is that 
we conducted a single- centre study. However, being a 
national referral hospital, the study site receives patients 
from all over the country.
Our study is probably the first of its kind in Africa to 
explore the prevalence and outcomes of AHRF in an 
adult population in a limited resource acute care setting.
The prevalence of AHRF among emergency depart-
ment patients in a tertiary hospital in an LIC was low 
but was associated with very high mortality. Pneumonia 
was the most common cause of AHRF. Severity of HIV 
co- infection, hypoxaemia, high LIPS, anaemia, thrombo-
cytopenia and being male were independently associated 
with death. This highlights the need for more work on 
early detection and management of AHRF in resource- 
limited settings.
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